How should peripheral arterial disease (PAD) be managed compared to deep vein thrombosis (DVT)?

Management of Peripheral Arterial Disease (PAD) vs Deep Vein Thrombosis (DVT)

PAD and DVT are fundamentally different vascular conditions requiring distinct management strategies: PAD is an arterial insufficiency disease treated with cardiovascular risk reduction, antiplatelet therapy, exercise, and selective revascularization, while DVT is a venous thrombotic disease managed with anticoagulation to prevent pulmonary embolism and post-thrombotic syndrome. 1, 2

Peripheral Arterial Disease (PAD) Management

Immediate Medical Therapy Foundation

All PAD patients require comprehensive cardiovascular risk reduction as the primary therapeutic priority, since they face higher risk of myocardial infarction and stroke than limb loss. 2, 3

Antiplatelet Therapy (Class I)

• Clopidogrel 75 mg daily is the preferred antiplatelet agent, providing 23.8% relative reduction in MI, stroke, or vascular death compared to aspirin 2
• Aspirin 75-325 mg daily is an acceptable alternative if clopidogrel is not tolerated 1, 2
• For high ischemic risk patients with non-high bleeding risk, consider adding rivaroxaban 2.5 mg twice daily to aspirin 100 mg daily 2, 3
• Dual antiplatelet therapy (aspirin + clopidogrel) is NOT recommended for standard PAD management (Class III) 2

Lipid Management (Class I)

• Initiate high-intensity statin therapy immediately to achieve ≥50% LDL-C reduction and target LDL-C <55 mg/dL (<1.4 mmol/L), regardless of baseline lipid levels 2, 3
• This aggressive lipid lowering is foundational therapy for all PAD patients 3

Blood Pressure Control

• Target <140/90 mmHg in non-diabetics or <130/80 mmHg in diabetics and chronic kidney disease patients 2, 3
• ACE inhibitors or ARBs are preferred first-line agents because they reduce cardiovascular events beyond blood pressure lowering alone 2, 3
• Beta-blockers are safe and effective in PAD—they do NOT worsen claudication despite historical concerns 2, 3

Smoking Cessation (Class I)

• Ask about tobacco use at every encounter and provide comprehensive cessation interventions 2, 3
• Offer pharmacotherapy: varenicline, bupropion, or nicotine replacement therapy unless contraindicated 3, 4

Diabetes Management

• Target HbA1c <7% to reduce microvascular complications and improve foot outcomes 2, 3
• Implement immediate proper foot care: appropriate footwear, daily inspection, skin cleansing, topical moisturizers, and urgent attention to any lesions 2, 3

Exercise Therapy (Class I - Initial Treatment)

Supervised exercise training is the first-line treatment for intermittent claudication before considering revascularization. 1, 2, 3

• Prescribe 30-45 minutes per session, ≥3 times weekly for minimum 12 weeks 1, 2, 3
• Walking to moderate-to-severe claudication pain under supervision yields superior results 2, 3
• Unsupervised exercise has uncertain effectiveness and should not replace supervised programs 2

Pharmacotherapy for Claudication

• Cilostazol 100 mg twice daily improves pain-free and peak walking distances as adjunct to exercise (Class IIa) 2
• Common adverse effects include headache, diarrhea, dizziness, and palpitations; approximately 20% discontinue within 3 months 2

Revascularization Decision Algorithm

Revascularization should only be considered after a mandatory 3-month trial of optimal medical therapy plus supervised exercise in patients with persistent lifestyle-limiting symptoms. 1, 2, 3

Indications for Revascularization:

• Lifestyle-limiting claudication unresponsive to 3 months of medical therapy and exercise with impaired quality of life 1, 2, 3
• Critical limb-threatening ischemia (CLTI) requires immediate revascularization 1, 3

NOT Indicated:

• Revascularization is NOT recommended for asymptomatic PAD or solely to prevent progression to CLTI 3
• Patients with normal post-exercise ABI do not need arterial imaging 1

Critical Limb-Threatening Ischemia (CLTI) Management

CLTI represents a vascular emergency requiring expedited evaluation and treatment. 1

• Immediate referral to vascular team for limb salvage 1, 3
• Revascularization as soon as possible 3
• Initiate systemic antibiotics promptly if infection present 1
• Refer to specialized wound care providers 1
• Offload mechanical stress to allow wound healing 3
• Patients at risk for CLI (ABI <0.4 with diabetes) require regular foot inspection 1

Follow-Up Protocol

• Annual follow-up minimum with vascular specialist assessing clinical/functional status, medication adherence, limb symptoms, and cardiovascular risk factors 1, 3
• After revascularization: ABI and duplex ultrasound at 1-3 months, 6 months, 12 months, then annually 3
• Patients with prior CLTI require evaluation at least twice annually due to high recurrence risk 1
• Duplex ultrasound surveillance is beneficial for infrainguinal autogenous vein bypass grafts 1

---

Deep Vein Thrombosis (DVT) Management

DVT is a venous thrombotic disease fundamentally different from PAD, requiring anticoagulation rather than antiplatelet therapy. 5

Acute DVT Treatment

• Full-dose anticoagulation with heparin (unfractionated or low-molecular-weight) is the cornerstone of acute DVT management 6, 5
• Anticoagulation prevents pulmonary embolism and reduces post-thrombotic syndrome (PTS) risk 5
• Approximately 30% of DVT patients will develop PTS despite anticoagulation alone 5

Advanced Therapies

• Pharmacomechanical catheter-directed thrombolysis (PCDT) may reduce PTS in severe proximal DVT cases 5
• The ATTRACT trial is evaluating PCDT plus anticoagulation versus anticoagulation alone 5

Prophylaxis in PAD Patients

• Low-dose heparin for venous thromboembolism prophylaxis is indicated during hospitalization for chronic critical limb ischemia 6

---

Key Distinctions Between PAD and DVT Management

PAD (Arterial Disease):

• Antiplatelet therapy (clopidogrel or aspirin) 1, 2
• Anticoagulation is contraindicated (Class III - Harm) for cardiovascular risk reduction in PAD 2
• Focus on cardiovascular risk reduction and exercise 1, 2, 3
• Revascularization only after failed medical therapy 1, 2, 3

DVT (Venous Disease):

• Anticoagulation (heparin, warfarin, DOACs) 6, 5
• Antiplatelet therapy has no role in acute DVT management 5
• Focus on preventing PE and PTS 5
• Thrombolysis considered in select cases 6, 5

Common Pitfalls

• Do not confuse peripheral edema with PAD—edema suggests venous disease, heart failure, or other systemic conditions, not arterial insufficiency 7
• Do not use warfarin for PAD cardiovascular risk reduction—this is a Class III (Harm) recommendation 2
• Do not proceed to revascularization without the mandatory 3-month trial of medical therapy and supervised exercise unless CLTI is present 1, 2, 3
• Beta-blockers are safe in PAD despite outdated concerns about worsening claudication 2, 3
• Do not delay anticoagulation in DVT to perform diagnostic testing—treatment should begin immediately 6